Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2022 –2029 | |
|
|
USD 145.53 Million |
| USD 413.54 Million | |
| % | |
Asia-Pacific Vagus Nerve Stimulation Market, By Product Type (Implantable VNS Devices and External VNS Devices), Biomaterial (Ceramics, Metallic, and Polymeric), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression and Anxiety, and Others), Patient Type (Adults, Pediatric, and Geriatric), End User (Hospitals, Ambulatory Surgery Centres, Specialty Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) industry trends and forecast to 2029.
The vagus nerve is a prominent component of the autonomic nervous system that regulates metabolic homeostasis and functions as a crucial component of the neuroendocrine-immune axis in maintaining homeostasis via its afferent and efferent pathways. Any approach that stimulates the vagus nerve, including manual or electrical stimulation, is referred to as Vagus Nerve Stimulation (VNS). For refractory epilepsy and treatment-resistant depression, left cervical VNS is an approved therapy.
According to the WHO, neurological diseases are responsible for 4.5% to 11% of all illnesses worldwide. Vagus nerve stimulators are also used to treat patients suffering from epilepsy, depression, asthma, and cardiovascular disorders.
The Asia-Pacific vagus nerve stimulation market is expected to grow in the forecast period of 2022 to 2029. Data Bridge Market Research analyzes that the market is growing with a CAGR of 14.0% in the forecast period of 2022 to 2029 and is expected to reach USD 413.54 million by 2029 from USD 145.53 million in 2021.
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Year
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Product Type (Implantable VNS Devices and External VNS Devices), Biomaterial (Ceramics, Metallic, and Polymeric), Application (Pain Management, Epileptic Seizures, Obesity Management, Depression and Anxiety, and Others), Patient Type (Adults, Pediatric, and Geriatric), End User (Hospitals, Ambulatory Surgery Centres, Specialty Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others).
|
|
Countries Covered
|
China, Japan, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and rest of Asia-Pacific.
|
|
Market Players Covered
|
Medtronic, LivaNova PLC, electroCore, Inc., Cirtec, Brain Control Co. Limited, Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc, Parasym Ltd, Neuropix Company Ltd,. and tVNS Technologies GmbH among others.
|
The vagus nerve is a long cranial nerve that runs from a person’s brain stem into the neck, chest, and abdomen. It is a part of the parasympathetic nervous system, which is commonly referred to as the rest-and-digest system because it regulates body functions while a person is at rest. It delivers messages to a person’s brain from their digestive system and organs such as their lungs, heart, and liver. It controls several organ functions, including digestion, heart rate, and respiratory rate. It is responsible for vasomotor activity and reflexes. It also regulates vocalization, mood, and immunity. It influences sensory functions in a person’s ears, sinuses, and esophagus as well.
VNS involves a pulse generator inserted under a person’s skin on their chest. The implantable device, which is similar to a pacemaker, delivers regular electrical pulses to the brain via the vagus nerve. It is possible to provide additional stimulation by placing the provided magnet over the pulse generator. Relaxation techniques such as breathing exercises, yoga, and medication can influence vagus nerve activity, increasing its ability to relieve anxiety and mood-related symptoms. VNS can improve an individual’s physical health and can offer benefits for several conditions such as epilepsy and depression. The treatment has a healing effect on a person’s body due to its ability to promote relaxation and reduce inflammation.
Drivers
Neurological disorders cause 4.5% to 11% of all illnesses, whether in low or high-income countries. The impact is greater compared to that of malignancies, gastrointestinal diseases, or respiratory illnesses, and it is expected to grow over the next years. One of the most common neurological conditions, epilepsy, affects almost every country on earth. Most people with this illness are seen among populations in nations like China and India. Due to this rising prevalence, there is a rising demand for a variety of tools and treatments, such as VNS. More neurological problems are being treated with VNS. In addition to other clinical uses, it aids in the treatment of neurological conditions like epilepsy and depression due to the significant prevalence of neurological conditions worldwide.
Traditional and conventional VNS devices are implanted in the patient's body and leads are placed on the vagus nerves that provide electrical stimulation when required. Growing demand and technological advancement of innovative devices lead to the introduction of small-sized implantable VNS devices in the market. These small-sized implantable devices offer various clinical benefits to patients and healthcare providers. The introduction of innovative devices is anticipated to boost the market growth.
Constant focus by market players to innovate and launch new products had led to the emergence of non-invasive VNS (nVNS) devices in the market. These devices are also known as transcutaneous VNS (tVNS) devices
The approval for VNS devices is governed by the U.S. FDA and the EU. The FDA issues a final protocol for filing a Pre-market Approval Application (PMA) or a notice of completion of a Product Development Protocol (PDP).
For instance,
The FDA has approved an implantable vagus nerve stimulator to treat epilepsy and depression. In addition, in Asia-Pacific, new nVNS devices that do not require surgical implantation to treat epilepsy, depression, and pain have been approved.
The approval received for VNS devices would result in the device being declared safe to use and ready for post-marketing approval. It would result in the supply and distribution of MRI machines to the developing markets, situated in the Asia-Pacific region. Hence, the rise in product approvals is expected to propel market growth.
Product development in recent years
Combination Therapies are much more effective than monotherapy, without additional side effects. They are a safe and effective alternative for individuals with refractory bladder conditions. Combining different target therapy strategies is the best approach to relieving patients of bladder disorders. Oral medication and behavioral therapy should be considered for the patients' refractory treatment. Various advanced target therapies are available such as sacral neuromodulation, intradetrusor injection of a botulinum toxin A, and percutaneous tibial nerve stimulation. These are advanced treatments and more effective as compared to oral agents.
Opportunities
Strategic initiatives by the key market players
The demand for VNS devices is increasing in the market owing to the increased levels of R&D; along with that, the market growth is being aided by the desire for innovative medications. Thus, the top market players have implemented new strategies by developing new devices and equipment as well as collaborating with other players in the market and aimed at improving business operations and profitability.
The companies operating in the Asia-Pacific region in this market are adopting collaboration as a strategy to increase their product portfolio with advanced technology-rich products to boost their business in various dimensions. Thus, increasing strategic initiatives by key market players are expected to offer significant opportunities for market players operating in the market.
Rising government initiatives for neurological disease
The purpose of funding for VNS devices is to encourage applications seeking to develop devices for various neurological disorders. Novel devices should move beyond existing electrical or magnetic stimulation and develop new stimulation techniques capable of increased spatiotemporal precision as well as multi-focal, closed-loop approaches. Therefore, the funding by the government would result in the safety of the patient and cost savings. In addition, hospitals and healthcare agencies would administer this treatment at a lower price through collaboration with government organizations. Hence, the advancements in R&D activities and funding by the government will act as an opportunity for this market growth.
Restraint/Challenge
The rise in the cost of VNS devices is due to technological development and increased demand for nVNS devices by neurologists in hospitals, clinics, nursing facilities, and ambulatory surgical centers. Overhead costs can help explain why hospitals charge so much for stimulation devices. The increased intricacy and cost of VNS devices, technological innovations, and robust investments would increase the costs. The increased cost would result in delayed treatment of patients in hospitals and clinics. Hence, the increased cost of VNS devices is expected to restrain market growth.
The COVID-19 outbreak had a drastic effect on Asia-Pacific healthcare with a number of countries most severely impacted. The pandemic had a negative impact on the market growth, on account of a temporary halt in research activities in this field, coupled with low influx of patients in hospitals and diagnostic centers.
Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology and test results involved in the pharmacogenetics testing market.
Recent Development
Asia-Pacific vagus nerve stimulation market is segmented into product type, biomaterial, application, patient type, end user, and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
Based on product type, the market is segmented into implantable VNS devices and external VNS devices.
Biomaterial
Based on biomaterial, the market is segmented into ceramics, metallic, and polymeric.
Application
Based on application, the market is segmented into pain management, epileptic seizures, obesity management, depression and anxiety, and others.
Patient Type
Based on patient type, the market is segmented into adults, pediatric, and geriatric.
End User
Based on end user, the market is segmented into hospitals, ambulatory surgery centers, specialty centers, and others.
Distribution Channel
Based on distribution channel, the market is segmented into direct tender, retail sales, and others.
The Asia-Pacific vagus nerve stimulation market is analyzed and market size insights and trends are provided by country, product type, biomaterial, application, patient type, end user, and distribution channel as referenced above.
China dominates the Asia-Pacific vagus nerve stimulation market in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the high prevalence and incidence of neurological disorders in the region, and growing R&D investments and the launch of new products are boosting market growth.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Asia-Pacific brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
The Asia-Pacific vagus nerve stimulation market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are Medtronic, LivaNova PLC, electroCore, Inc., Cirtec, Brain Control Co. Limited, Soterix Medical Inc., SetPoint Medical, MicroTransponder Inc, Parasym Ltd, Neuropix Company Ltd., and tVNS Technologies GmbH among others.
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by the DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, APAC vs. Regional, and Vendor Share Analysis. Please request an analyst call in case of further inquiry.
SKU-
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA PACIFIC VAGUS NERVE STIMULATION MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 LIFELINE CURVE , BY PRODUCT TYPE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
4.3 KEY STRATEGIC INITIATIVES
5 REGULATIONS OF ASIA PACIFIC VAGUS NERVE STIMULATION MARKET
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 INCREASING PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS
6.1.2 INNOVATIVE NON-INVASIVE VAGUS NERVE STIMULATION DEVICES INTRODUCED TO MEET DEMAND
6.1.3 RISE IN PRODUCT APPROVALS
6.1.4 PRODUCT DEVELOPMENT IN RECENT YEARS
6.2 RESTRAINTS
6.2.1 HIGH MAINTENANCE AND DEVICE COSTS TO RESTRAIN ADOPTION OF VAGUS NERVE STIMULATORS
6.2.2 RISE IN PRODUCT RECALL
6.2.3 UNFAVORABLE REIMBURSEMENT POLICIES
6.3 OPPORTUNITIES
6.3.1 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS
6.3.2 RISING GOVERNMENT INITIATIVES FOR NEUROLOGICAL DISEASE
6.4 CHALLENGES
6.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES
6.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS
6.4.3 STRINGENT REGULATIONS FOR APPROVAL OF MEDICAL DEVICES
7 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE
7.1 OVERVIEW
7.2 IMPLANTABLE VNS DEVICE
7.3 EXTERNAL VNS DEVICE
8 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL
8.1 OVERVIEW
8.2 METALLIC
8.3 POLYMERIC
8.4 CERAMICS
9 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 EPILEPTIC SEIZURES
9.2.1 IMPLANTABLE VNS DEVICE
9.2.2 EXTERNAL VNS DEVICE
9.3 DEPRESSION AND ANXIETY
9.3.1 IMPLANTABLE VNS DEVICE
9.3.2 EXTERNAL VNS DEVICE
9.4 PAIN MANAGEMENT
9.4.1 IMPLANTABLE VNS DEVICE
9.4.2 EXTERNAL VNS DEVICE
9.5 OBESITY MANAGEMENT
9.5.1 IMPLANTABLE VNS DEVICE
9.5.2 EXTERNAL VNS DEVICE
9.6 OTHERS
10 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE
10.1 OVERVIEW
10.2 ADULTS
10.2.1 IMPLANTABLE VNS DEVICES
10.2.2 EXTERNAL VNS DEVICES
10.3 GERIATRIC
10.3.1 IMPLANTABLE VNS DEVICES
10.3.2 EXTERNAL VNS DEVICES
10.4 PEDIATRIC
10.4.1 IMPLANTABLE VNS DEVICES
10.4.2 EXTERNAL VNS DEVICES
11 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY END USER
11.1 OVERVIEW
11.2 SPECIALTY CENTERS
11.3 HOSPITALS
11.4 AMBULATORY SURGICAL CENTERS (ASCS)
11.5 OTHERS
12 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT TENDER
12.3 RETAIL SALES
12.4 OTHERS
13 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY REGION
13.1 ASIA-PACIFIC
13.1.1 CHINA
13.1.2 JAPAN
13.1.3 SOUTH KOREA
13.1.4 INDIA
13.1.5 AUSTRALIA
13.1.6 SINGAPORE
13.1.7 THAILAND
13.1.8 MALAYSIA
13.1.9 INDONESIA
13.1.10 PHILIPPINES
13.1.11 REST OF ASIA-PACIFIC
14 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 ELECTROCORE, INC.
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENTS
16.2 LIVANOVA PLC
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 MEDTRONIC
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 SETPOINT MEDICAL
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 TVNS TECHNOLOGIES GMBH
16.5.1 COMPANY SNAPSHOT
16.5.2 COMPANY SHARE ANALYSIS
16.5.3 PRODUCT PORTFOLIO
16.5.4 RECENT DEVELOPMENT
16.6 NEUROPIX COMPANY LTD.
16.6.1 COMPANY SNAPSHOT
16.6.2 PRODUCT PORTFOLIO
16.6.3 RECENT DEVELOPMENT
16.7 BRAIN CONTROL CO. LTD
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 CIRTEC
16.8.1 COMPANY SNAPSHOT
16.8.2 PRODUCT PORTFOLIO
16.8.3 RECENT DEVELOPMENTS
16.9 MICROTRANSPONDER INC.
16.9.1 COMPANY SNAPSHOT
16.9.2 PRODUCT PORTFOLIO
16.9.3 RECENT DEVELOPMENT
16.1 PARASYM LTD
16.10.1 COMPANY SNAPSHOT
16.10.2 PRODUCT PORTFOLIO
16.10.3 RECENT DEVELOPMENT
16.11 RESHAPE LIFESCIENCES INC. (2021)
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 SOTERIX MEDICAL INC.
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENTS
17 QUESTIONNAIRE
18 RELATED REPORTS
TABLE 1 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 2 ASIA PACIFIC IMPLANTABLE VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 3 ASIA PACIFIC EXTERNAL VNS DEVICES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 5 ASIA PACIFIC METALLIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 ASIA PACIFIC POLYMERIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 ASIA PACIFIC CERAMICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 9 ASIA PACIFIC EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 ASIA PACIFIC EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 11 ASIA PACIFIC DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 12 ASIA PACIFIC DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 13 ASIA PACIFIC PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 14 ASIA PACIFIC PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 15 ASIA PACIFIC OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 16 ASIA PACIFIC OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 17 ASIA PACIFIC OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 18 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 19 ASIA PACIFIC ADULTS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 ASIA PACIFIC ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 21 ASIA PACIFIC GERIATRICS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 22 ASIA PACIFIC GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 23 ASIA PACIFIC PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 ASIA PACIFIC PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 25 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 26 ASIA PACIFIC SPECIALTY CENTERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 ASIA PACIFIC HOSPITALS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 ASIA PACIFIC AMBULATORY SURGICAL CENTERS (ASCS) IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 29 ASIA PACIFIC OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 ASIA PACIFIC DIRECT TENDER IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 ASIA PACIFIC RETAIL SALES IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 33 ASIA PACIFIC OTHERS IN VAGUS NERVE STIMULATION MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 34 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 35 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 36 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 37 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 38 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 39 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 40 ASIA-PACIFIC EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 41 ASIA-PACIFIC DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 42 ASIA-PACIFIC PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 43 ASIA-PACIFIC OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 44 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 45 ASIA-PACIFIC ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 46 ASIA-PACIFIC GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 47 ASIA-PACIFIC PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 48 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 49 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 50 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 51 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 52 CHINA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 53 CHINA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 54 CHINA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 CHINA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 56 CHINA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 57 CHINA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 58 CHINA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 CHINA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 60 CHINA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 61 CHINA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 62 CHINA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 63 CHINA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 64 CHINA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 65 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 66 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 67 JAPAN VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 68 JAPAN VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 69 JAPAN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 70 JAPAN EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 71 JAPAN DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 72 JAPAN PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 73 JAPAN OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 74 JAPAN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 75 JAPAN ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 76 JAPAN GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 77 JAPAN PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 78 JAPAN VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 79 JAPAN VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 80 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 81 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 82 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 83 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 84 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 85 SOUTH KOREA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 86 SOUTH KOREA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 87 SOUTH KOREA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 SOUTH KOREA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 89 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 90 SOUTH KOREA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 91 SOUTH KOREA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 92 SOUTH KOREA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 93 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 94 SOUTH KOREA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 95 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 96 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 97 INDIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 98 INDIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 99 INDIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 100 INDIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 101 INDIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 102 INDIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 103 INDIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 104 INDIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 105 INDIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 106 INDIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 107 INDIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 108 INDIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 INDIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 111 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 112 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 113 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 114 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 115 AUSTRALIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 116 AUSTRALIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 117 AUSTRALIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 118 AUSTRALIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 119 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 120 AUSTRALIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 121 AUSTRALIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 122 AUSTRALIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 123 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 124 AUSTRALIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 125 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 126 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 127 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 128 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 129 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 130 SINGAPORE EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 131 SINGAPORE DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 132 SINGAPORE PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 133 SINGAPORE OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 134 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 135 SINGAPORE ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 136 SINGAPORE GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 137 SINGAPORE PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 138 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 139 SINGAPORE VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 140 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 141 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 142 THAILAND VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 143 THAILAND VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 144 THAILAND VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 145 THAILAND EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 146 THAILAND DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 147 THAILAND PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 148 THAILAND OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 149 THAILAND VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 150 THAILAND ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 151 THAILAND GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 152 THAILAND PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 153 THAILAND VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 154 THAILAND VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 155 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 156 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 157 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 158 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 159 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 160 MALAYSIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 161 MALAYSIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 162 MALAYSIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 163 MALAYSIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 164 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 165 MALAYSIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 166 MALAYSIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 167 MALAYSIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 168 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 169 MALAYSIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 170 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 171 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 172 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 173 INDONESIA VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 174 INDONESIA VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 175 INDONESIA EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 176 INDONESIA DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 177 INDONESIA PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 178 INDONESIA OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 179 INDONESIA VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 180 INDONESIA ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 181 INDONESIA GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 182 INDONESIA PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 183 INDONESIA VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 184 INDONESIA VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 185 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 186 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 187 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 188 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY BIOMATERIAL, 2020-2029 (USD MILLION)
TABLE 189 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 190 PHILIPPINES EPILEPTIC SEIZURES IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 191 PHILIPPINES DEPRESSION AND ANXIETY IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 192 PHILIPPINES PAIN MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 193 PHILIPPINES OBESITY MANAGEMENT IN VAGUS NERVE STIMULATION MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 194 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 195 PHILIPPINES ADULTS IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 196 PHILIPPINES GERIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 197 PHILIPPINES PEDIATRIC IN VAGUS NERVE STIMULATION MARKET, BY PATIENT TYPE, 2020-2029 (USD MILLION)
TABLE 198 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 199 PHILIPPINES VAGUS NERVE STIMULATION MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 200 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 201 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (VOLUME)
TABLE 202 REST OF ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
FIGURE 1 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: SEGMENTATION
FIGURE 2 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: DATA TRIANGULATION
FIGURE 3 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: DROC ANALYSIS
FIGURE 4 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: ASIA PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: DBMR MARKET POSITION GRID
FIGURE 8 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: SEGMENTATION
FIGURE 11 THE GROWING DEMAND FOR INNOVATIVE NON–INVASIVE VAGUS STIMULATION DEVICES AND THE INCREASED PREVALENCE OF NEUROLOGICAL DISORDERS ARE EXPECTED TO DRIVE THE ASIA PACIFIC VAGUS NERVE STIMULATION MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 IMPLANTABLE VNS DEVICE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA PACIFIC VAGUS NERVE STIMULATION MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE ASIA PACIFIC VAGUS NERVE STIMULATION MARKET
FIGURE 14 INCIDENCE OF ADULT-ONSET BRAIN DISORDERS IN THE U.S. IN 2021
FIGURE 15 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2021
FIGURE 16 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 17 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 18 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 19 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2021
FIGURE 20 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, 2022-2029 (USD MILLION)
FIGURE 21 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, CAGR (2022-2029)
FIGURE 22 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY BIOMATERIAL, LIFELINE CURVE
FIGURE 23 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2021
FIGURE 24 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY APPLICATION, 2022-2029 (USD MILLION)
FIGURE 25 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY APPLICATION, CAGR (2022-2029)
FIGURE 26 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 27 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2021
FIGURE 28 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, 2022-2029 (USD MILLION)
FIGURE 29 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, CAGR (2022-2029)
FIGURE 30 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY PATIENT TYPE, LIFELINE CURVE
FIGURE 31 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY END USER, 2021
FIGURE 32 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY END USER, 2022-2029 (USD MILLION)
FIGURE 33 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY END USER, CAGR (2022-2029)
FIGURE 34 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY END USER, LIFELINE CURVE
FIGURE 35 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 36 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 37 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 38 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 39 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: SNAPSHOT (2021)
FIGURE 40 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021)
FIGURE 41 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2022 & 2029)
FIGURE 42 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY COUNTRY (2021 & 2029)
FIGURE 43 ASIA-PACIFIC VAGUS NERVE STIMULATION MARKET: BY PRODUCT TYPE (2022 - 2029)
FIGURE 44 ASIA PACIFIC VAGUS NERVE STIMULATION MARKET: COMPANY SHARE 2021 (%)
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.